Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Salgotarjan – page 7

270 clinical trials in Salgotarjan, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salgotarjan at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Salgotarjan

Open in trial search

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Astrazeneca AB

Bladder cancer

Recruiting

Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen - Cilag International

Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen - Cilag International

Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Belinostat
  • Sponsor:Acrotech Biopharma Inc.

Cystic fibrosis

Recruiting

Study on the Safety and Effects of SPL84 for Patients with Cystic Fibrosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPL84-23-1
  • Sponsor:Splisense Ltd.

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Seizure

Recruiting

Study on the Safety and Effectiveness of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Psychotic disorder+1

Recruiting

Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer's-Related Psychosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Salgotarjan

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Advanced metastatic breast cancer treatments
  • Triple-negative breast cancer therapies
  • Hormone therapy resistance studies

Research includes evaluation of new drug combinations and sequential therapy approaches for improved patient outcomes.

02 Lung Cancer Studies

Groundbreaking research on non-small cell lung cancer treatments, particularly focusing on advanced and metastatic cases with specific biomarker profiles.

  • PD-L1 positive NSCLC treatments
  • Combination immunotherapy approaches
  • Stage III unresectable cancer therapies

Studies emphasize personalized treatment approaches based on molecular markers.

03 Head and Neck Cancer

Clinical trials investigating new treatments for head and neck squamous cell carcinoma, including both HPV-negative and recurrent/metastatic cases.

  • Novel combination therapies
  • Immunotherapy applications
  • Treatment for recurrent disease

Research focuses on improving survival rates through innovative therapeutic combinations.

04 Prostate Cancer Innovations

Studies addressing metastatic castration-resistant prostate cancer, evaluating new treatment options and therapeutic combinations.

  • Novel hormonal therapies
  • Treatment-resistant cases
  • Combination therapy approaches

Trials aim to improve outcomes for patients with advanced disease stages.

05 Cardiovascular Research

Studies examining treatments for cardiovascular diseases and related conditions, including stroke prevention and obesity management.

  • Acute ischemic stroke treatments
  • Obesity management in CVD patients
  • Prevention strategies

Research focuses on both therapeutic interventions and preventive approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.